Your browser doesn't support javascript.
loading
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications / 한국역학회지
Epidemiology and Health ; : e2021022-2021.
Article in En | WPRIM | ID: wpr-890618
Responsible library: WPRO
ABSTRACT
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
Full text: 1 Index: WPRIM Language: En Journal: Epidemiology and Health Year: 2021 Type: Article
Full text: 1 Index: WPRIM Language: En Journal: Epidemiology and Health Year: 2021 Type: Article